SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections in the United States and internationally. Its lead product candidate, ibrexafungerp, is an innovative oral and intravenous treatment aimed at addressing various fungal infections, including vulvovaginal candidiasis and invasive candidiasis. The drug has successfully completed Phase 2 clinical trials for vulvovaginal candidiasis. Additionally, SCYNEXIS engages in drug discovery and development across multiple therapeutic areas, including antibacterials, antivirals, and oncology. The company also provides contract research services, such as medicinal chemistry and cGMP manufacturing, to pharmaceutical and life science partners. Founded in 1999 and originally known as SCYNEXIS Chemistry & Automation, Inc., the company changed its name in 2002 and is headquartered in Jersey City, New Jersey.